Solvay $123 Mil. Unimed Buy Brings Three Drugs, 40 Reps
Executive Summary
Solvay is paying $123 mil. in cash for Unimed's three marketed products, one pending NDA and a sales force of 40. Brussels-based Solvay announced the deal on June 11, agreeing to pay $12 per share for the nearly 9 mil. outstanding Unimed shares.
You may also be interested in...
GlobeXPharma.com May Pursue Rx Reimportation; Kapoor Is Founder
The Internet pharmaceutical purchasing site GlobeXPharma.com could become one source of reimported pharmaceuticals once pending drug importation legislation is passed.
GlobeXPharma.com May Pursue Rx Reimportation; Kapoor Is Founder
The Internet pharmaceutical purchasing site GlobeXPharma.com could become one source of reimported pharmaceuticals once pending drug importation legislation is passed.
Solvay To Submit Audits To FDA Shortly In Effort To Be Removed From AIP List
Solvay has indicated that the independent audits analyzing stability data generated by its manufacturing facilities will be submitted shortly to FDA as a step in being removed from the agency's application integrity policy list.